Segall Bryant & Hamill LLC Buys 42,836 Shares of Embecta Corp. (NASDAQ:EMBC)

Segall Bryant & Hamill LLC grew its stake in shares of Embecta Corp. (NASDAQ:EMBC) by 40.7% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 148,145 shares of the company’s stock after buying an additional 42,836 shares during the quarter. Segall Bryant & Hamill LLC owned approximately 0.25% of Embecta worth $3,059,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the stock. Smartleaf Asset Management LLC grew its position in Embecta by 175.1% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,216 shares of the company’s stock worth $25,000 after acquiring an additional 774 shares during the last quarter. Victory Capital Management Inc. grew its holdings in shares of Embecta by 5.6% during the fourth quarter. Victory Capital Management Inc. now owns 17,489 shares of the company’s stock worth $361,000 after purchasing an additional 923 shares during the last quarter. Inspire Advisors LLC increased its stake in shares of Embecta by 3.7% in the fourth quarter. Inspire Advisors LLC now owns 32,307 shares of the company’s stock valued at $667,000 after buying an additional 1,138 shares during the period. JPMorgan Chase & Co. raised its holdings in Embecta by 1.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 145,269 shares of the company’s stock valued at $2,048,000 after buying an additional 1,600 shares during the last quarter. Finally, Natixis Advisors LLC boosted its position in Embecta by 5.7% during the 3rd quarter. Natixis Advisors LLC now owns 30,735 shares of the company’s stock worth $433,000 after buying an additional 1,648 shares during the period. 93.83% of the stock is currently owned by institutional investors and hedge funds.

Embecta Trading Down 0.7 %

EMBC stock opened at $12.43 on Friday. Embecta Corp. has a 1-year low of $9.93 and a 1-year high of $21.48. The stock has a 50-day moving average price of $15.39 and a 200-day moving average price of $16.28. The firm has a market cap of $722.61 million, a PE ratio of 12.43, a price-to-earnings-growth ratio of 0.78 and a beta of 1.27.

Embecta (NASDAQ:EMBC) last posted its quarterly earnings results on Thursday, February 6th. The company reported $0.65 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.45 by $0.20. Embecta had a negative return on equity of 19.22% and a net margin of 5.25%. On average, analysts forecast that Embecta Corp. will post 2.85 earnings per share for the current year.

Embecta Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, March 14th. Shareholders of record on Friday, February 28th were paid a $0.15 dividend. This represents a $0.60 annualized dividend and a yield of 4.83%. The ex-dividend date of this dividend was Friday, February 28th. Embecta’s dividend payout ratio (DPR) is currently 60.00%.

Insider Transactions at Embecta

In related news, Director Milton Mayo Morris sold 3,100 shares of the stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $16.38, for a total value of $50,778.00. Following the transaction, the director now directly owns 36,133 shares in the company, valued at $591,858.54. This trade represents a 7.90 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 0.42% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Morgan Stanley upgraded shares of Embecta from an “underweight” rating to an “equal weight” rating and boosted their price target for the stock from $13.00 to $20.00 in a research report on Monday, December 2nd.

Embecta Profile

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.